Literature DB >> 21452413

Increasing trend in infection-related death-censored graft failure in renal transplantation.

Ravi Parasuraman1, Marwan Abouljoud, Gordan Jacobsen, Gampala Reddy, Alan Koffron, K K Venkat.   

Abstract

BACKGROUND: Advances in kidney transplantation have significantly improved early outcomes but failed to improve long-term graft survival. Despite many causes, the contribution of infection to death-censored graft failure (DCGF) is unknown. The aim of our study is to assess the impact of infections on DCGF using United Network for Organ Sharing data.
METHODS: We analyzed 38,286 DCGFs among 189,110 first kidney transplants performed between January 1, 1990 and December 31, 2006. Information on infection contributing to DCGF was available in 31,326 DCGF recipients. Student's two-sample t test for normally distributed variables, Wilcoxon rank sum test for nonnormally distributed, and Chi-square test for categorical variables were used in univariable comparisons. Multivariable logistic regression analysis was performed to assess the independent contribution of variables to infection-related DCGF.
RESULTS: Overall, infection accounted for 7.7% (2397/31,326) of all DCGF. The rate of infection-related DCGF increased from 6.4% in 1990 to 10.1% in 2006 and was significantly higher during 1997 to 2006 when compared with 1990 to 1996 period (9.1% vs. 6.3%, P<0.001). Over these 17 years, the trends in infection-related DCGF and rejection rates showed an inverse relationship with the former exceeding the latter starting in 2005. The risk of infection-related DCGF was higher (14.1%) in recipients older than 65 years and exceeded the rejection rate in those older than 60 years. Urological complications and polyoma infection were the most significant risk factors with odds ratios of 8.77 (confidence interval: 5.15-14.93) and 2.55 (confidence interval: 1.41-4.61), respectively.
CONCLUSION: Infection is increasingly contributing to DCGF in recent years and warrant reevaluation of current immunosuppression protocols, especially in older recipients.

Entities:  

Mesh:

Year:  2011        PMID: 21452413     DOI: 10.1097/tp.0b013e3181fdd96c

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  6 in total

1.  Dynamics of urinary polyomavirus shedding in healthy adult women.

Authors:  Courtney L Kling; Alexandra T Wright; Sophie E Katz; Gloria B McClure; J Suzette Gardner; Jason T Williams; Natalie M Meinerz; Robert L Garcea; John A Vanchiere
Journal:  J Med Virol       Date:  2012-09       Impact factor: 2.327

2.  A Critical Analysis of the Specific Pharmacist Interventions and Risk Assessments During the 12-Month TRANSAFE Rx Randomized Controlled Trial.

Authors:  Haley M Gonzales; James N Fleming; Mulugeta Gebregziabher; Maria Aurora Posadas Salas; John W McGillicuddy; David J Taber
Journal:  Ann Pharmacother       Date:  2021-09-08       Impact factor: 3.463

3.  Pharmacist-Led Mobile Health Intervention and Transplant Medication Safety: A Randomized Controlled Clinical Trial.

Authors:  Haley M Gonzales; James N Fleming; Mulugeta Gebregziabher; Maria Aurora Posadas-Salas; Zemin Su; John W McGillicuddy; David J Taber
Journal:  Clin J Am Soc Nephrol       Date:  2021-04-30       Impact factor: 8.237

Review 4.  Immunosuppression trends in solid organ transplantation: The future of individualization, monitoring, and management.

Authors:  Nicole A Pilch; Lyndsey J Bowman; David J Taber
Journal:  Pharmacotherapy       Date:  2020-12-30       Impact factor: 4.705

5.  Infection-related hospitalizations over 30 years of follow-up in patients starting renal replacement therapy at pediatric age.

Authors:  Danilo Lofaro; Judith L Vogelzang; Karlijn J van Stralen; Kitty J Jager; Jaap W Groothoff
Journal:  Pediatr Nephrol       Date:  2016-02       Impact factor: 3.714

6.  Improving Transplant Medication Safety Through a Pharmacist-Empowered, Patient-Centered, mHealth-Based Intervention: TRANSAFE Rx Study Protocol.

Authors:  James N Fleming; Frank Treiber; John McGillicuddy; Mulugeta Gebregziabher; David J Taber
Journal:  JMIR Res Protoc       Date:  2018-03-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.